

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

Case Report Form

Note: Data will be entered by participating sites directly into the study's REDCap online database.

DEMOGRAPHICS

<u>SUBJECT INFO:</u>	
Study ID	
YEAR of ED arrival	
Gender	
Age	
Race	White Black Hispanic Asian Native·Am Pacific Is Other Unknown
Latino	Yes No
Weight (kg)	
Height (cm)	
BMI	

TRAUMA DATA

Mechanism	Blunt	Penetrating	
Mechanism Type:	GSW Crush Fall Hanging	MultiGSW SW Burn FoundDown	MVC MCC Ped vs Auto Burn w/Inhalation Other Unknown
Mechanism Notes:			

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

COMORBIDITIES AND HIV DATA

COMORBIDITIES					
HIV / AIDS	Yes				
Hepatic Failure or Cirrhosis	Yes	No			
Immunosuppression	Yes	No			
Chronic Lung Disease (Asthma, COPD, Interstitial Lung Disease)	Yes	No			
Hepatitis C	Yes	No.	If yes, Hep C treated?	Yes	No
CAD (hx of MI, CABG, PTCA)	Yes	No			
ESRD	Yes	No			
Diabetes Mellitus	Yes	No	If yes, Insulin required?	Yes	No
CHF	Yes	No			
Active Malignancy	Yes	No	If yes, specify:		
Psych Disorder	Yes	No	If yes, specify:		
Comorbidity Notes:					
HIV DATA					
Currently on ARVs on admit?	Yes	No	Unknown		
Prior history of ARVs?	Yes	No	Unknown		
CD4 COUNT					
Last CD4 Count <u>Prior</u> to admit	Unknown				
Date of last CD4 (list as # of days prior to admit):	Unknown				
First CD4 Count <u>After</u> admit	Not done				
Date of post-admit CD4 count (list as # of says from hospital admission)					
VIRAL LOAD					
Viral Load <u>Prior</u> to admit	Unknown				
Date of Viral Load (list as # of days prior to admit):	Unknown				
First Viral Load <u>After</u> admit	Not done				
Date of post-admit Viral Load (list as # of says from hospital admission)					

The Role of HIV in Post-Injury Coagulation
WTA Multicenter Study

OUTPATIENT MEDICATIONS

NOACs/Anticoagulants/Antiplatelets: Outpatient		
NOACs Including: Pradaxa (dabigatran) Xarelto (rivaroxaban) Eliquis (apixaban) Savaysa (edoxaban) Bevyxxa (betrixaban)	Yes	No
Standard Anticoagulants Including: Coumadin (warfarin) Lovenox (enoxaparin)	Yes	No
Aspirin	Yes	No
Antiplatelets, other than aspirin Including: Aggrenox (aspirin/dipyridamole) Plavix (clopidogrel)	Yes	No
OTHER not captured above, please list:		

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

LAB SAMPLES

Admit (HR 0 Labs)

LAB SAMPLES			
HEMATOLOGY			CHEMISTRY
WBC (k/uL)			Creatinine (mg/dL)
Hemoglobin (g/dL)			Total Bili (mg/dL)
Hematocrit (%)			Calcium (mg/dL)
Platelet (k/uL)			Ionized Calcium (mmol/L)
WBC Differential			COAGULATION
Absolute Neutrophil			PT (sec)
Absolute Lymphocyte			PTT (sec)
Absolute Monocyte			INR
Absolute Eosinophil			Fibrinogen (mg/dL)
Absolute Basophil			
Absolute Large Lymphocyte			OTHER
			Lactate (mmol/L)
			Blood Type
Blood Gas			Albumin (g/dL) <i>*first within 1 wk</i>
<u>Please specify Venous or Arterial Blood gas:</u>	VBG	ABG	Prealbumin (mg/dL) <i>*first within 1 wk</i>
pH			CRP (mg/L) <i>*first within 1 wk</i>
pCO ₂			
pO ₂			
HCO ₃ ⁻			
Base deficit / excess			
*please use minus sign for base deficit, ex: base deficit -4.0, or base excess 4.0			

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

INPATIENT MEDICATIONS

NOACs/Anticoagulants/Antiplatelets: Inpatient			
Collect to first 28 days in hospital			
NOACs Including: Pradaxa (dabigatran) Xarelto (rivaroxaban) Eliquis (apixaban) Savaysa (edoxaban) Bevyxxa (betrixaban)	Yes	No	Start date (days from admit): _____
Standard Anticoagulants Including: Coumadin (warfarin)	Yes	No	Start date (days from admit): _____
Aspirin	Yes	No	Start date (days from admit): _____
Antiplatelets, other than aspirin Including: Aggrenox (aspirin/dipyridamole) Plavix (clopidogrel)	Yes	No	Start date (days from admit): _____
DVT Prophylaxis	Yes	No	Start date (days from admit): _____
Medication	Enoxaparin	Heparin	Other
Dosage (Dose/Route/Frequency)			
Total number of doses prescribed (aka optimal number of doses given, if none were missed or held) <i>Example: On morning of hospital day 3, patient started on Enoxaparin 30mg SC BID, discharged afternoon of hospital day 10; optimal total doses = 15</i>			
Total number of doses NOT given (held or missed)			
Heparin gtt	Yes	No	Start date (days from admit): _____
Therapeutic Enoxaparin	Yes	No	Start date (days from admit): _____
OTHER not captured above, please list:			

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

HEMOSTATIC MEDICATIONS

Collect to first 28 days in hospital. Collect start date, dosage, and number of doses given.

Cyklokapron (Tranexamic Acid)	Yes No Start date (days from admit): _____ Dosage (dose/route/frequency): _____ Number of doses given: _____
RiaSTAP (Fibrinogen Concentrate)	Yes No Start date (days from admit): _____ Dosage (dose/route/frequency): _____ Number of doses given: _____
KCentra (Prothrombin complex concentration)	Yes No Start date (days from admit): _____ Dosage (dose/route/frequency): _____ Number of doses given: _____
Factor VII	Yes No Start date (days from admit): _____ Dosage (dose/route/frequency): _____ Number of doses given: _____

MOF SCORING DATA

	Admit Day	Day 1	Day 2	Day 3	Day 4	Day 6	Day 6	Day 7
Pulmonary: Lowest P/F ratio*								
Renal: Highest creatinine								
Cardiac: Vasopressors**	Yes No	Yes No	Yes No	Yes No	Yes No	Yes No	Yes No	Yes No
Hepatic: Highest total bilirubin								

*No OR values for lowest P/F; **Do not record Yes for vasopressors required if ONLY used in the OR

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

OUTCOMES

THROMBOEMBOLIC COMPLICATIONS					
Thromboembolic Complication	Yes	No			
Time of complication (# of hours from admit)					
Type of Complication	DVT	PE	MI	CVA	Other
Thromboembolic complication description					
Type of Diagnosis	Incidental		Symptomatic		
Diagnoses by	CT	Ultrasound	Other.		
Mortality @28 days	Alive	Dead	ISS		
Vital Status at hospital discharge	Alive	Dead	AIS Head		
Date time of death (# of hours from Admit)			AIS Face		
Total Hospital Days			AIS Chest		
ICU Days (to 28days)			AIS Abdomen		
Vent Days (to 28days)			AIS Extremity		
			AIS Skin		
Discharge Location	Expired	Home			
	SNF	Rehab			
	Txf to Another Hospital				
	AMA	Inpatient Psych			
	Other: _____				

The Role of HIV in Post-Injury Coagulation

WTA Multicenter Study

FUNCTIONAL COAGULATION MEASURES

Please record any functional coagulation results your site obtains:

TEG – any test – and/or ROTEM. It is not necessary to have both TEG and ROTEM, either is fine!

Date time of blood sample collection (minutes from hospital arrival):

ROTEM:

EXTEM:

Ex CT
Ex CFT
Ex Alpha
Ex A10
Ex A20
Ex MCF
Ex ML

FIBTEM:

Fib CT
Fib Alpha
Fib A10
Fib A20
Fib MCF
Fib ML

INTEM:

In CT
In CFT
In Alpha
In A10
In A20
In MCF
In ML

APTEM:

Ap CT
Ap CFT
Ap Alpha
Ap A10
Ap A20
Ap MCF
Ap ML

TEG:

Citrated Rapid TEG:

CRT ACT
CRT SP
CRT R
CRT K
CRT Alpha
CRT MA
CRT G
CRT Ly30

Citrated Kaolin:

CK SP
CK R
CK K
CK Alpha
CK MA
CK G
CK Ly30

Functional Fibrinogen:

FF FLEV
FF SP
FF R
FF K
FF Alpha
FF MA
FF G
FF EPL
FF Ly34